Skip to main content

Advertisement

Table 1 Age at treatment initiation and short-term GH treatment outcomes in children born SGA

From: Early diagnosis and treatment referral of children born small for gestational age without catch-up growth are critical for optimal growth outcomes

Study N Design/Duration Agea/Model Outcome (∆HSDS or statistical model) P Value
Argente 2007 [46] 39b MC, C, R, O/2 years 2 to <4 years 1.7 at 1 year; approximately 2.5 at 2 years <0.05
    4 to 5 years 1.2 at 1 year; approximately 1.8 at 2 years  
Carvalho-Furtado 2009 [47] 39 Ob/1 year Prepubertal 0.75 =0.016
    Pubertal 0.40  
Lee 2008 [16] 433 MC, NordiNet IOS/≥1 year Mean age 6.7 to 9.3 6.7 years = 1.0 and 0.8; 7.6 years = 0.72; 8.3 years = 0.61; 9.3 years = 0.57 <0.0001c
Ranke 2003 [19] 613 year 1; KIGS, clinical trials/2 years Mean age 6.6/statistical models predicting growth response Year 1: GH dose (35% of variability), age at treatment start (11% of variability) <0.0001 <0.0001
  385 year 2    Year 2: HV in year 1 of treatment (29% of variability), age at treatment start (3% of variability), GH dose (2% of variability)  
Ross 2010 [15] 208 year 1;119 year 2 ANSWER Program registry/2 years Mean age 8.4/males <11 years vs ≥11 years; females <10 years vs ≥10 years Year 1 boys: <11 years = 0.82; ≥11 years = 0.27Year 1 girls: <10 years = 0.58; ≥10 years = 0.41Year 2 boys: <11 years = 1.23; ≥11 years = 0.59Year 2 girls: <10 years = 1.00; ≥10 years = 0.87 <0.0001 = 0.093 = 0.0005 = 0.56
  1. aAge at treatment initiation; bData are reported for study group 1 with 2 years GH treatment; cMultivariate analysis showed ∆HSDS was dependent on age at the start of treatment. ANSWER, American Norditropin Studies: Web-enabled Research; C, controlled; GH, growth hormone; ∆HSDS, change in height SDS; HV, height velocity; IOS, international outcome study; KIGS, Pharmacia International Growth Database; MC, multicenter; O, open trial; Ob, observational; R, randomized; SDS, standard deviation score.